Liquid Biopsy Test Detects More than 50 Cancer Types

Grail has some solid results coming from its multi-cancer early detection blood test. The liquid biopsy specialist revealed data that shows its technology can detect more than 50 cancer types across all stages, with a very low false-positive rate of less than 1%, through a single blood draw. These results were published in Annals of Oncology. Grail’s Circulating Cell-Free Genome Atlas (CCGA) study provided much of the data for the publication. The study included more than 15,000 participants with or without a diagnosis of cancer. In the sub-study reported in Annals of Oncology (N=6,689), results from the validation set (N=1,969) showed Grail’s proprietary targeted methylation technology achieved high specificity (99.3%), or a single low false-positive rate of less than 1%, across more than 50 cancer types. The detection rate for a pre-specified set of 12 deadly cancer types, that together account for approximately 63% of U.S. cancer deaths annually, was 67.3% across stages I-III (95% confidence interval [CI]: 60.7-73.3%). The overall detection rate for all cancer types was 43.9% across stages I-III (95% CI: 39.4-48.5%). When a cancer signal was detected, a tissue of origin result was provided for 96% of the samples, and of these, the test correctly identified the tissue of origin in 93% of cases. Importantly, the performance of the test was consistent across training and validation sets. "The promising results from this independent validati...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news